Journal Article

DZNE-2020-04433

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Neurotropic growth factors and glycosaminoglycan based matrices to induce dopaminergic tissue formation.

Schurig, K. (First author)DZNE* ; Zieris, A. ; Hermann, A.DZNE* ; Freudenberg, U. ; Heidel, S. ; Grimmer, M. ; Storch, A.DZNE* ; Werner, C. (Corresponding author)

2015
Elsevier Science Amsterdam [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/j.biomaterials.2015.07.029

Abstract: Current cell replacement therapies in Parkinson's disease (PD) are limited by low survival of transplanted cell and lacking regeneration of neuronal circuitries. Therefore, bioartificial cell carriers and growth/differentiation factors are applied to improve the integration of transplants and maximize newly generated and/or residual dopaminergic function. In this work, biohybrid poly(ethylene glycol) (starPEG)-heparin hydrogels releasing fibroblast growth factor 2 (FGF-2) and glial-derived neurotrophic factor (GDNF) were used to trigger dopaminergic tissue formation by primary murine midbrain cells in vitro. Matrix-delivered FGF-2 enhanced cell viability while release of GDNF had a pro-neuronal/dopaminergic effect. Combined delivery of both factors from the glycosaminoglycan-based matrices resulted in a tremendous improvement in survival and maturation capacity of dopaminergic neurons as obvious from tyrosine hydroxylase expression and neurite outgrowth. The reported data demonstrate that glycosaminoglycan-based hydrogels can facilitate the administration of neurotrophic factors and are therefore instrumental in potential future treatments of PD.

Keyword(s): Animals (MeSH) ; Cell Differentiation: drug effects (MeSH) ; Cell Survival: drug effects (MeSH) ; Cells, Cultured (MeSH) ; Dopaminergic Neurons: cytology (MeSH) ; Dopaminergic Neurons: drug effects (MeSH) ; Drug Liberation (MeSH) ; Female (MeSH) ; Fetus: cytology (MeSH) ; Fibroblast Growth Factor 2: pharmacology (MeSH) ; Glial Cell Line-Derived Neurotrophic Factor: pharmacology (MeSH) ; Glycosaminoglycans: pharmacology (MeSH) ; Heparin: chemistry (MeSH) ; Hydrogels: chemical synthesis (MeSH) ; Mesencephalon: cytology (MeSH) ; Mice, Inbred C57BL (MeSH) ; Nerve Growth Factors: pharmacology (MeSH) ; Neural Stem Cells: cytology (MeSH) ; Neural Stem Cells: drug effects (MeSH) ; Neurites: drug effects (MeSH) ; Neurites: metabolism (MeSH) ; Neuroglia: cytology (MeSH) ; Neuroglia: drug effects (MeSH) ; Polyethylene Glycols: chemical synthesis (MeSH) ; Tissue Engineering: methods (MeSH) ; Glial Cell Line-Derived Neurotrophic Factor ; Glycosaminoglycans ; Hydrogels ; Nerve Growth Factors ; Fibroblast Growth Factor 2 ; Polyethylene Glycols ; Heparin

---

Contributing Institute(s):

1. Non-Motor Symptoms in Parkinson's disease (AG Storch)
2. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)

Research Program(s):

1. 344 - Clinical and Health Care Research (POF3-344) (POF3-344)

Appears in the scientific report 2015

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---